Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces oncology conference focus

Novartis announces oncology conference focus

16th May 2008

The latest data on Novartis’s cancer treatment RAD001, or everolimus, will be a key feature of the company’s presentations at the annual meeting of the American Society of Clinical Oncology.

Novartis hopes the drug is a new treatment option for patients with advanced kidney cancer that has not responded to standard therapies.

The late-breaking data will be presented orally to delegates at the meeting, which is in its 44th year.

Novartis plans to give a comprehensive overview of its research and development in more than 170 abstracts, including details of the first efficacy results from the ABCSG-12 study into the impact of Zometa on total remission in patients who have had early breast cancer.

President and chief executive of the firm’s oncology unit, David Epstein, said: “This is a particularly exciting year for Novartis Oncology in advancing research and touching the lives of thousands of cancer patients.”

Novartis’s areas of focus are cardiovascular and metabolism, oncology and haematology, neuroscience and ophthalmics, respiratory, immunology and infectious diseases.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.